| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5808146 | BLUE EARTH | Amino acid analogs for tumor imaging |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9387266 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(2 years from now) | |
| US10953112 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(2 years from now) | |
| US10010632 | BLUE EARTH | Precursor compound of radioactive halogen-labeled organic compound |
Nov, 2026
(2 years from now) | |
| US10967077 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10124079 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10933147 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
| US10716868 | BLUE EARTH | Imaging of metastatic or recurrent cancer |
Dec, 2035
(11 years from now) | |
Axumin is owned by Blue Earth.
Axumin contains Fluciclovine F-18.
Axumin has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Axumin are:
- US5808146
Axumin was authorised for market use on 27 May, 2016.
Axumin is available in solution;intravenous dosage forms.
Axumin can be used as method of diagnosing tumors using positron emission tomography, positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment.
Drug patent challenges can be filed against Axumin from 27 May, 2020.
The generics of Axumin are possible to be released after 30 December, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2021 |
Drugs and Companies using FLUCICLOVINE F-18 ingredient
NCE-1 date: 27 May, 2020
Market Authorisation Date: 27 May, 2016
Treatment: Method of diagnosing tumors using positron emission tomography; Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate speci...
Dosage: SOLUTION;INTRAVENOUS
AXUMIN family patents
